Biotech company Alzheon Inc. just raised $50 million in venture capital to complete clinical trials of an oral medication which will be used to treat Alzheimer’s disease. The drug will be tested in a late-stage Phase 3 clinical trial with 300 people. If the study is successful, Alzheon expects to seek FDA approval for the drug in 2024. Sadly, another recent drug to hit the market called Aduhelm by Biogen is not available for widespread use after Medicare said last week it would only cover the cost of the drug for patients enrolled in a clinical trial.
